(Human) HER2 Antibody - Trastuzumab Biosimilar

Anti-HER2 (CD340) - Trastuzumab biosimilar - CAS #180288-69-1

Anti-HER2-Tra-hIgG1 is a biosimilar research antibody to Trastuzumab. Trastuzumab is humanized IgG1 monoclonal antibody that targets the human epidermal growth factor receptor 2 (HER2). HER2, also known as ERBB2 or HER2/neu, plays an important role in normal cell growth and differentiation [1]. Particularly in breast and ovarian cancers, HER2 is over-expressed and causes uncontrollable cell proliferation. Binding of trastuzumab to HER2 results in cell death through different mechanisms, including antibody-dependent cell-mediated cytotoxicity and phagocytosis [2, 3]. Trastuzumab has been approved by the FDA for the treatment of breast cancer.

Anti-HER2-Tra-hIgG1 comprises the variable region of Trastuzumab and a human IgG1 constant region mediating high effector functions. For applications requiring low Fc effector activity, InvivoGen also offers Anti-HER2-Tra-hIgG4 (S228P), an Vorsetuzumab-based research antibody. 

This mAb can be used together with InvivoGen's Raji-HER2 cell line to study antibody-dependent effector functions, such as antibody-dependent cellular cytotoxicity (ADCC), either with peripheral blood mononuclear cells or T cell-derived Jurkat reporter cells (see figure).

Key features

• Each lot is functionally tested and validated.
• The complete sequence of the antibody construct was verified.
• The absence of endotoxins is determined by the EndotoxDetect™ assay.

References:

1. Rubin I. & Yarden Y. 2001. The basic biology of HER2. Ann Oncol.12 Suppl 1:S3-8.
2. Collins DM. et al., 2012. Trastuzumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) in HER-2-non-amplified breast cancer cell lines. Ann Oncol. 23(7):1788-95.
3. Petricevic B. et al., 2013. Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patients. J Transl Med. 11:307.